Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic Q2 Revenues Jump 45 Percent on Assay Services

NEW YORK – SomaLogic said after the close of the market on Monday that its second quarter revenues grew 45 percent year over year.

For the three months ended June 30, SomaLogic reported revenues of $20.5 million, compared to $14.1 million in Q2 2022, beating the consensus Wall Street estimate of $19.8 million.

Assay services revenues were $16.6 million, up 52 percent from $10.9 million a year ago, while product revenues grew fourfold to $2.9 million from $714,000. Other revenues were $200,000, down 88 percent from $1.7 million a year ago.

"Our second quarter results are in line with our expectations despite navigating operational changes and a dynamic macroeconomic backdrop," Adam Taich, interim CEO, said in a statement. "While our progress this quarter in both core assay services and distributed kits is encouraging, there is still more work to be done."

SomaLogic said it has appointed Eliot Lurier as interim CFO.

The firm's net loss for the quarter was $24.8 million, or $.13 per share, compared to a loss of $23.0 million, or $.13 per share, in the year ago quarter, beating the consensus Wall Street estimate of a $.16 loss per share.

R&D expenses for the quarter were $10.8 million, down 39 percent from $17.6 million a year ago, while SG&A expenses were $29.6 million, down 20 percent from $36.8 million a year ago. SomaLogic said in a statement that this decrease aligns with the company's previously announced initiatives to reduce expenses.

SomaLogic ended the quarter with cash and cash equivalents of $354.5 million and investments of $119.6 million.

The firm reiterated full-year 2023 revenue guidance in the range of $80 million to $84 million.

In Tuesday morning trading on the Nasdaq, shares of Somalogic were up 11 percent at $2.26.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.